

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application.

**Listing of Claims:**

1-47 (Canceled)

48. (Withdrawn) A method of screening a test composition for G protein-coupled receptor (GPCR) agonist activity against multiple GPCRs, comprising:

(a) providing a mixture of cells comprising a first cell and a second cell, said first cell comprising a first GPCR and a first conjugate, said second cell comprising a second GPCR and a second conjugate;

(b) exposing said mixture of cells to a test composition;

(c) detecting said first and second conjugates for an indication of GPCR agonist activity.

49. (Withdrawn) The method of Claim 48, wherein at least one conjugate comprises a marker molecule and a protein.

50. (Withdrawn) The method of Claim 49, wherein the marker molecule comprises a radioisotope, enzyme, fluorescent group, chemiluminescent group or any combination thereof.

51. (Withdrawn) The method of Claim 49, wherein the marker molecule comprises an epitope tag, affinity label or combination thereof.

52. (Withdrawn) The method of Claim 49, wherein said marker molecule is a fluorescent protein.

53. (Withdrawn) The method of Claim 52, wherein said fluorescent protein is green fluorescent protein (GFP).

54. (Withdrawn) The method of Claim 49, wherein said protein is an arrestin.

55. (Withdrawn) The method of Claim 48, wherein said first and second conjugates are the same.

56. (Withdrawn) The method of Claim 48, wherein said first and second GPCRs interact with different  $G_{\alpha}$  protein subunits.

57. (Withdrawn) The method of Claim 48, wherein said indication of GPCR agonist activity is translocation or localization of at least one conjugate.

58. (Withdrawn) The method of Claim 48, wherein said indication of GPCR agonist activity is translocation or localization of at least one conjugate to a vesicle, endosome, granule or pit.

59. (Withdrawn) The method of Claim 48, wherein said indication of GPCR agonist activity is an increase in translocation or localization of at least one conjugate, after exposure said mixture of cells to said test composition.

60. (Withdrawn) The method of Claim 48, wherein said indication of GPCR agonist activity is an increase level of translocation or localization of at least one conjugate, with respect to a predetermined level of translocation or localization of at least one conjugate.

61. (Previously Presented) A method of screening a test composition for G protein-coupled receptor (GPCR) agonist activity against multiple GPCRs, comprising:

(a) providing a cell comprising a first GPCR, a first conjugate associated with the desensitization pathway of said first GPCR, a second GPCR different from said first GPCR, and a second conjugate associated with the desensitization pathway of said second GPCR;

(b) exposing said cell to a test composition;

(c) detecting said first and second conjugates for an indication of GPCR agonist activity.

62. (Previously Presented) The method of Claim 61, wherein at least one conjugate comprises a marker molecule and a protein.
63. (Previously Presented) The method of Claim 62, wherein the marker molecule comprises a radioisotope, enzyme, fluorescent group, chemiluminescent group or any combination thereof.
64. (Previously Presented) The method of Claim 62, wherein the marker molecule comprises an epitope tag, affinity label, or combination thereof.
65. (Previously Presented) The method of Claim 62, wherein said marker molecule is a fluorescent protein.
66. (Previously Presented) The method of Claim 65, wherein said fluorescent protein is green fluorescent protein (GFP).
67. (Previously Presented) The method of Claim 62, wherein said protein is an arrestin.
68. (Previously Presented) The method of Claim 61, wherein said first and second conjugates are the same.
69. (Previously Presented) The method of Claim 61, wherein said first and second GPCRs interact with different  $G_\alpha$  protein subunits.
70. (Previously Presented) The method of Claim 61, wherein said indication of GPCR agonist activity is translocation or localization of at least one conjugate.
71. (Previously Presented) The method of Claim 61, wherein said indication of GPCR agonist activity is translocation or localization of at least one conjugate to a vesicle, endosome, granule or pit.

72. (Previously Presented) The method of Claim 61 wherein said indication of GPCR agonist activity is an increase in translocation or localization of at least one conjugate, after exposure of said cell to said test composition.

73. (Previously Presented) The method of Claim 61, wherein said indication of GPCR agonist activity is an increase level of translocation or localization of at least one conjugate, with respect to a predetermined level of translocation or localization of at le